IRX-101 for Eye Pain After Injections
This study is testing a new eye drop called IRX-101. It's designed to see how safe and well-tolerated IRX-101 is compared to povidone-iodine, which is a common antiseptic, in people who get injections in their eye for retinal disease. The main goal is to see if IRX-101 can reduce eye pain one hour after these injections. You can join if you are 18 or older and are already receiving anti-VEGF injections in your eye. The study is looking for 240 participants, but its current status is unclear.
- Study design
- This is a randomized, double-masked study comparing IRX-101 to povidone-iodine. It plans to enroll 240 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint assesses pain one hour after injection, but overall follow-up duration is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Stephen Smith, MD · STUDY_CHAIR · Founder
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Assessment of post-intravitreal injection eye painDemonstrate a reduction in mean 1-hr post-injection pain scores
Demonstrate the superiority of IRX-101 compared to PI in terms of reducing patient-reported post-intravitreal injection eye pain; pain will be assessed using the visual analog pain scale, a validated patient-reported outcome measure (questionnaire) for assessing patient's subjective pain and discomfort